Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement
暂无分享,去创建一个
Douglas K Owens | Aaron B Caughey | Karina W Davidson | Alex H Krist | Kirsten Bibbins-Domingo | Carol M Mangione | David C Grossman | Chien-Wen Tseng | K. Bibbins-Domingo | Chyke A Doubeni | M. Ebell | A. Caughey | D. Grossman | C. Mangione | D. Owens | A. Kemper | A. Krist | K. Davidson | J. Epling | S. Curry | C. Landefeld | M. Silverstein | M. Simon | Chien-Wen Tseng | A. Siu | Albert L Siu | Alex R Kemper | Martha Y. Kubik | C Seth Landefeld | John W Epling | Martha Kubik | Michael Silverstein | Susan J Curry | Mark Ebell | Melissa A Simon | M. Kubik | C. Tseng | Michael Silverstein | Kirsten Bibbins-Domingo
[1] Martin Fortin,et al. Canadian Task Force on Preventive Health Care , 2012 .
[2] Jianfeng Xu,et al. Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening. , 2015, The Journal of urology.
[3] Virginia Moyer,et al. The US Preventive Services Task Force , 2015, North Carolina Medical Journal.
[4] M. Stampfer,et al. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate‐specific Antigen‐era , 2015, International journal of cancer.
[5] T. Tammela,et al. Family history in the Finnish Prostate Cancer Screening Trial , 2015, International journal of cancer.
[6] Hans Garmo,et al. Radical prostatectomy or watchful waiting in early prostate cancer. , 2014, The New England journal of medicine.
[7] David Gillatt,et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.
[8] T. Tammela,et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.
[9] J. Kaprio,et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.
[10] Timothy J Wilt,et al. Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.
[11] J. Sterne,et al. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial , 2018, JAMA.
[12] F. Hamdy,et al. Measuring the psychosocial impact of population‐based prostate‐specific antigen testing for prostate cancer in the UK , 2006, BJU international.
[13] L. Holmberg,et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. , 2011, The Lancet. Oncology.
[14] T. Tammela,et al. Prostate cancer mortality in the Finnish randomized screening trial. , 2013, Journal of the National Cancer Institute.
[15] J. Gohagan,et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years , 2017, Cancer.
[16] M. Cooperberg,et al. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.
[17] J. Hugosson,et al. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. , 2015, European urology.
[18] T. Wilt,et al. Follow‐up of Prostatectomy versus Observation for Early Prostate Cancer , 2017, The New England journal of medicine.
[19] V. Moyer,et al. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.
[20] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[21] D. Bates,et al. The impact of a suspicious prostate biopsy on patients’ psychological, socio-behavioral, and medical care outcomes , 2006, Journal of General Internal Medicine.
[22] Ahmedin Jemal,et al. Annual Report to the Nation on the Status of Cancer, 1975‐2012, featuring the increasing incidence of liver cancer , 2016, Cancer.
[23] M. Roobol,et al. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. , 2002, Urology.
[24] Anssi Auvinen,et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). , 2012, European urology.
[25] S. Freedland,et al. Five-year downstream outcomes following prostate-specific antigen screening in older men. , 2013, JAMA internal medicine.
[26] Mohammad Hassan Murad,et al. Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.
[27] T. Tammela,et al. False-positive screening results in the European randomized study of screening for prostate cancer. , 2011, European journal of cancer.
[28] H. Parnes,et al. Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial , 2014, BJU international.
[29] H. Bang,et al. Prostate-Specific Antigen–Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force , 2018, JAMA.
[30] David Gillatt,et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. , 2016, The New England journal of medicine.
[31] E. Steyerberg,et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC , 2010, International journal of cancer.
[32] Timothy J Wilt,et al. Prevention and early detection of prostate cancer. , 2014, The Lancet. Oncology.
[33] M. Tonelli,et al. Recommendations on screening for prostate cancer with the prostate-specific antigen test , 2014, Canadian Medical Association Journal.
[34] Chris Metcalfe,et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study , 2012, BMJ : British Medical Journal.
[35] P. Prorok,et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial , 2010, Clinical trials.
[36] Douglas K Owens,et al. Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians , 2013, Annals of Internal Medicine.
[37] D. Katz,et al. Health perceptions in patients who undergo screening and workup for prostate cancer. , 2007, Urology.